Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.35 |
| ▸ | IL1B | P01584 | 7/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27379422 | 1.00 | P2RX7 (0.35) | P2RX7IL1BNR3C2TP53FFAR4 | |
| SCHEMBL27377777 | 0.88 | GPR119 (0.36) | P2RX7IL1B | |
| SCHEMBL30755349 | 0.88 | GPR119 (0.36) | P2RX7IL1B | |
| SCHEMBL30755526 | 0.86 | NR1H2 (0.34) | P2RX7IL1BTP53 | |
| SCHEMBL27379106 | 0.86 | NR1H2 (0.34) | P2RX7IL1BTP53 | |
| SCHEMBL27379394 | 0.85 | HSD11B1 (0.39) | P2RX7IL1BNR3C2TP53RORC | |
| SCHEMBL27374381 | 0.83 | MEN1 (0.35) | P2RX7IL1B | |
| SCHEMBL27375857 | 0.80 | MEN1 (0.36) | P2RX7IL1BTP53RORC | |
| SCHEMBL30755212 | 0.78 | CA12 (0.37) | P2RX7IL1BRORCHSD11B1 | |
| SCHEMBL27378973 | 0.78 | MEN1 (0.38) | P2RX7IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |